m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03979)
Name
AMG 757
Status
Phase 1
TTD Drug ID
D7IA0N
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Delta-like protein 3 (DLL3)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Delta-like protein 3 (DLL3) is a therapeutic target for AMG 757. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 757 through regulating the expression of Delta-like protein 3 (DLL3). [1], [2]
References
Ref 1 N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 2 Clinical pipeline report, company report or official report of Harpoon Therapeutics.